Tobey J. MacDonald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tobey J. MacDonald has a total of 460 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Lenzen
Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL
10 shared publications - Anna Vinitsky
St. Jude Children's Research Hospital 13 Memphis
10 shared publications - Arzu Onar-Thomas
Department of Biostatistics, St. Jude Children’s Research Hospital , Memphis, Tennessee
10 shared publications - Benjamin Kovacic
Department of Cancer Sciences, Cleveland Clinic, Cleveland, OH 44195
10 shared publications - C. Marcela Diaz-Montero
Cleveland Clinic 7 Cleveland, OH
10 shared publications - Catherine A. Billups
St. Jude Children's Research Hospital 2 Memphis, TN
10 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Flow diagram summarizing duration of therapy and DLTs for patients on both strata.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Flow diagram summarizing duration of therapy and DLTs for patients on both strata.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Mean (±SD) serum sotigalimab concentration–time profiles at the 0.6 mg/kg dose (DL3) in Cycle 1 and Cycle 2 (pooled across strata). Sampling occurred pre-dose, at end of infusion (EOI), and at 4, 24 ± 1, and 168 ± 4 hours from infusion start; nominal times are plotted. Concentrations at pre-dose and 168 hours were BLQ (0.010 µg/mL). Error bars represent SD; n per timepoint: Cycle 1, 15–17; Cycle 2, 12–13.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Mean (±SD) serum sotigalimab concentration–time profiles at the 0.6 mg/kg dose (DL3) in Cycle 1 and Cycle 2 (pooled across strata). Sampling occurred pre-dose, at end of infusion (EOI), and at 4, 24 ± 1, and 168 ± 4 hours from infusion start; nominal times are plotted. Concentrations at pre-dose and 168 hours were BLQ (0.010 µg/mL). Error bars represent SD; n per timepoint: Cycle 1, 15–17; Cycle 2, 12–13.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Swimmers plot showing time on treatment for each patient (sorted by stratum and longest duration on treatment).
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Swimmers plot showing time on treatment for each patient (sorted by stratum and longest duration on treatment).
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Select cytokine profiles of those cytokines IL-8, IFN-γ, IL-6, and TNF-α which met limit of detection across the cohort.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Select cytokine profiles of those cytokines IL-8, IFN-γ, IL-6, and TNF-α which met limit of detection across the cohort.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Patient characteristics for eligible subjects (n=31)
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Patient characteristics for eligible subjects (n=31)
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Metadata summary of all deidentified patients used for all analyses.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Metadata summary of all deidentified patients used for all analyses.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Supplementary Table 3 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Supplementary Table 3 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Representativeness of Study Participants
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Representativeness of Study Participants
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Supplementary Table 4 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
Supplementary Table 4 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG
- Open Access
- 18 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1812994
The tumor microenvironment of medulloblastoma: from emerging biological insights to novel therapeutic targeting
Medulloblastoma is the most common pediatric malignancy of the brain and spine and a major cause of childhood cancer-related morbidity and mortality. Novel therapeutic approaches are urgently needed. The malignant behavior of this disease is influenced both by cell intrinsic factors and by the complex interactions of the tumor cells with its tumor microenvironment. Recent scientific and technological advancements allow increased ability to interrogate the microenvironment in terms of composition and cellular and signaling crosstalk, which together are critical for the regulation of tumor survival, disease proliferation, metastasis, and response to treatment. We summarize the current understanding of the medulloblastoma tumor microenvironment and explore its influence on disease pathogenesis, as well as identify emerging opportunities to leverage the microenvironment as a novel therapeutic target.
- 18 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1812994
Open AccessThe tumor microenvironment of medulloblastoma: from emerging biological insights to novel therapeutic targeting
Medulloblastoma is the most common pediatric malignancy of the brain and spine and a major cause of childhood cancer-related morbidity and mortality. Novel therapeutic approaches are urgently needed. The malignant behavior of this disease is influenced both by cell intrinsic factors and by the complex interactions of the tumor cells with its tumor microenvironment. Recent scientific and technological advancements allow increased ability to interrogate the microenvironment in terms of composition and cellular and signaling crosstalk, which together are critical for the regulation of tumor survival, disease proliferation, metastasis, and response to treatment. We summarize the current understanding of the medulloblastoma tumor microenvironment and explore its influence on disease pathogenesis, as well as identify emerging opportunities to leverage the microenvironment as a novel therapeutic target.